6533b81ffe1ef96bd1277959

RESEARCH PRODUCT

Regorafenib dose escalations in the prospective, observational CORRELATE study in patients with metastatic colorectal cancer

Emmanuelle DochyJ. O’connorSabine Fiala-buskiesAndrés CervantesMichel DucreuxAlfredo Falcone

subject

Oncologymedicine.medical_specialtyColorectal cancerbusiness.industryHematologymedicine.diseasechemistry.chemical_compoundOncologychemistryInternal medicineRegorafenibmedicineIn patientObservational studybusinesshttps://doi.org/10.1093/annonc/mdz156.028